All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Novel radiopharmaceutical agents based on monoclonal and recombinant antibodies.

Public support

  • Provider

    Ministry of Industry and Trade

  • Programme

    Project consortia

  • Call for proposals

    Projektová konsorcia 3 (SMPO200300001)

  • Main participants

    EXBIO Praha, a.s.

  • Contest type

    VS - Public tender

  • Contract ID

Alternative language

  • Project name in Czech

    Vývoj nových radiofarmak na bázi monoklonárních a rekombinantních protilátek.

  • Annotation in Czech

    Vývoj zcela nového typu radiofarmaceutických preparátů na bázi monoklonálních a rekombinantních protilátek. Výsledkem budou nové lékové formy připravené ke klinickým testům.

Scientific branches

  • R&D category

    VV - Exeperimental development

  • CEP classification - main branch

    EI - Biotechnology and bionics

  • CEP - secondary branch

    FD - Oncology and haematology

  • CEP - another secondary branch

  • OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

    20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30204 - Oncology<br>30205 - Hematology<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics

Completed project evaluation

  • Provider evaluation

    U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

  • Project results evaluation

    Acceptable

Solution timeline

  • Realization period - beginning

    Jan 1, 2003

  • Realization period - end

    Jan 1, 2005

  • Project status

    U - Finished project

  • Latest support payment

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP06-MPO-FD-U/02:2

  • Data delivery date

    Feb 19, 2007

Finance

  • Total approved costs

    24,154 thou. CZK

  • Public financial support

    14,900 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    9,255 thou. CZK